CuATSM – A Promising Compound

CuATSM – A Promising Compound
Researchers from an Australian biotech company called Collaborative Medicinal Development recently presented positive data from their Phase I clinical trial of a compound called CuATSM. The results suggested that 24 weeks of treatment with CuATSM was safe and well tolerated, and the participants experienced a marked improvement in their Parkinson's(PD) symptoms (based on the total UPDRS clinical rating scale and ... read more
Source: The Cure Parkinson’s TrustPublished on 2019-06-20